📋 Key Information Summary
- Acute tubular necrosis (ATN) is the most common cause of intrinsic acute kidney injury (AKI), accounting for 45–50 % of all inpatient AKI in Australia.
- ATN results from injury to renal tubular epithelial cells and is classified into ischaemic and nephrotoxic aetiologies; many patients have both.
- Ischaemic ATN typically follows prolonged hypotension, sepsis, major surgery, or cardiopulmonary bypass — oligo-anuria and a rising creatinine are hallmarks.
- Nephrotoxic ATN is caused by aminoglycosides, IV contrast media, NSAIDs, amphotericin B, cisplatin, and endogenous toxins (myoglobin, urate).
- The diagnostic hallmark on urine microscopy is muddy-brown granular casts and renal tubular epithelial (RTE) cells — distinguish from bland urinary sediment in pre-renal azotaemia.
- Fractional excretion of sodium (FENa) > 2 % and urine osmolality < 350 mOsm/kg suggest ATN; exceptions include ATN in the setting of CKD, diuretics, or contrast nephropathy.
- There is no specific pharmacological therapy to reverse established ATN; management is supportive — volume optimisation, nephrotoxin avoidance, and electrolyte correction.
- Renal replacement therapy (RRT) is indicated for refractory hyperkalaemia, severe metabolic acidosis, fluid overload, uraemic symptoms, or complications of uraemia.
- Prevention centres on pre-procedural hydration with isotonic crystalloid (e.g., 0.9 % NaCl 1 mL/kg/hr for 6–12 hours before IV contrast), avoidance of nephrotoxins, and haemodynamic optimisation.
- Risk stratification using KDIGO AKI staging (creatinine rise and urine output) guides escalation of care and nephrology referral thresholds.
- Aboriginal and Torres Strait Islander peoples experience significantly higher rates of AKI requiring RRT — remote-area management strategies and culturally safe care are essential.
- Recovery typically occurs within 7–21 days in uncomplicated ATN; prolonged non-recovery should prompt consideration of cortical necrosis, interstitial nephritis, or thrombotic microangiopathy.
Introduction & Australian Epidemiology
Acute tubular necrosis (ATN) is the most common cause of intrinsic acute kidney injury (AKI) and represents direct injury to renal tubular epithelial cells by ischaemic, nephrotoxic, or mixed mechanisms. ATN is characterised by a rapid decline in glomerular filtration rate (GFR), tubular dysfunction, and the presence of muddy-brown granular casts in the urinary sediment.
In Australia, AKI complicates 5–7 % of all hospital admissions and up to 30 % of intensive care unit (ICU) admissions, with ATN accounting for approximately 45–50 % of all intrinsic AKI episodes. The annual incidence of AKI requiring renal replacement therapy (RRT) in Australia is approximately 11 per 100,000 population, and this figure is considerably higher among Aboriginal and Torres Strait Islander peoples.
Clinical impact: In-hospital mortality for severe AKI (KDIGO stage 3) ranges from 30–50 %. Even patients who recover renal function are at significantly elevated risk of developing chronic kidney disease (CKD) and end-stage kidney disease (ESKD) over the subsequent 5–10 years.
ATN is categorised into two broad pathophysiological groups:
- Ischaemic ATN — results from prolonged renal hypoperfusion; most common in critically ill patients, perioperative settings, and sepsis.
- Nephrotoxic ATN — results from direct tubular toxicity by exogenous or endogenous nephrotoxins.
Many clinical scenarios involve overlapping mechanisms (e.g., sepsis + aminoglycosides, surgery + IV contrast).
Pathophysiology: Ischaemic vs Nephrotoxic
Ischaemic ATN
Ischaemic ATN occurs when renal blood flow is critically reduced to levels that compromise cellular oxygen delivery. The outer medulla (S3 segment of the proximal tubule and medullary thick ascending limb of the loop of Henle) is particularly vulnerable because of its high metabolic demand and relatively low baseline oxygen tension.
1
Initiation phase
Hypoperfusion leads to ATP depletion, intracellular calcium overload, generation of reactive oxygen species (ROS), and activation of apoptotic pathways in tubular epithelial cells.
2
Extension phase
Reperfusion injury amplifies damage. Endothelial cells release inflammatory cytokines (IL-6, IL-18, TNF-α), recruit neutrophils, and promote microvascular congestion. Tubular cells undergo apoptosis or necrosis and shed into the lumen.
3
Maintenance phase
GFR is low due to tubular obstruction (cellular debris, casts), back-leak of filtrate across damaged epithelium, vasoconstriction (tubuloglomerular feedback activation), and reduced ultrafiltration coefficient.
4
Recovery phase
Surviving tubular cells de-differentiate, proliferate, and re-differentiate to restore epithelial integrity. Polyuric phase ensues as tubular concentrating ability is impaired. Full GFR recovery may take weeks to months.
Nephrotoxic ATN
Nephrotoxic ATN results from direct chemical injury to tubular epithelial cells, predominantly affecting the proximal tubule (S1–S3 segments) where active transport and accumulation of toxins occur.
| Nephrotoxin | Mechanism | Key Risk Factors |
|---|---|---|
| Aminoglycosides (gentamicin, tobramycin) | Accumulation in proximal tubular cells → lysosomal phospholipidosis, mitochondrial dysfunction, apoptosis | Prolonged course (> 5–7 days), elevated trough levels, concurrent vancomycin, pre-existing CKD |
| Iodinated contrast media | Direct tubular toxicity + medullary vasoconstriction → contrast-induced AKI (CI-AKI) | eGFR < 45 mL/min, diabetes, dehydration, myeloma, high contrast volume |
| Amphotericin B (deoxycholate formulation) | Direct tubular toxicity + distal tubular acidosis; less nephrotoxicity with lipid formulations | Cumulative dose > 2–3 g, pre-existing renal impairment |
| NSAIDs | Inhibition of prostaglandin synthesis → afferent arteriolar vasoconstriction; direct tubular injury | CKD, dehydration, concurrent ACEi/ARB, heart failure, cirrhosis |
| Cisplatin | Proximal tubular injury, mitochondrial ROS, DNA damage | Dose-dependent (> 50 mg/m²), cumulative dosing, dehydration |
| Myoglobin (rhabdomyolysis) | Tubular obstruction + direct oxidative toxicity + renal vasoconstriction | Crush injury, prolonged immobilisation, extreme exertion, drug-induced (statins) |
| Uric acid (tumour lysis syndrome) | Intratubular crystallisation + inflammatory injury | Haematological malignancies, bulky tumour burden |
Key distinction: Ischaemic ATN preferentially damages the outer medulla (pars recta, mTAL) while nephrotoxic ATN more commonly affects the proximal convoluted tubule. In practice, ischaemic and nephrotoxic insults frequently co-exist.
Clinical Features & Laboratory Findings
Clinical Presentation
ATN typically presents in the setting of a predisposing event (surgery, sepsis, nephrotoxin exposure). Key clinical features include:
- Oliguria or anuria: Urine output < 400 mL/day (oliguria) or < 100 mL/day (anuria) — though non-oliguric ATN is increasingly recognised, particularly in nephrotoxic aetiologies.
- Rising serum creatinine: Typically increases by 26–44 µmol/L/day depending on catabolic state; may be masked by reduced muscle mass in elderly or critically ill patients.
- Fluid overload: Peripheral oedema, pulmonary oedema, hypertension.
- Uraemic symptoms: Nausea, vomiting, anorexia, encephalopathy, pericarditis (late/untreated).
- Electrolyte abnormalities: Hyperkalaemia, hyperphosphataemia, hypocalcaemia, metabolic acidosis, hyperuricaemia.
Laboratory Findings in ATN
| Parameter | ATN | Pre-Renal AKI |
|---|---|---|
| Fractional excretion of sodium (FENa) | > 2 % | < 1 % |
| Urine sodium (UNa) | > 40 mmol/L | < 20 mmol/L |
| Urine osmolality | < 350 mOsm/kg (isosthenuric) | > 500 mOsm/kg |
| Urine:plasma creatinine ratio | < 20 | > 40 |
| BUN:creatinine ratio | < 15 : 1 | > 20 : 1 |
| Fractional excretion of urea (FEUrea) | > 35 % | < 35 % |
| Response to volume challenge | No improvement | Improvement in UO/creatinine |
Caveat — FENa can be misleading: In ATN occurring with concurrent diuretic use, CKD, sepsis with early ATN, or contrast nephropathy, FENa may be < 1 %. In these situations, fractional excretion of urea (FEUrea > 35 %) is more reliable. Always interpret urine biochemistry in clinical context.
KDIGO AKI Staging
AKI severity should be staged using the Kidney Disease: Improving Global Outcomes (KDIGO) criteria:
Stage 1
KDIGO Stage 1
Creatinine rise ≥ 26.5 µmol/L within 48 hrs, OR 1.5–1.9× baseline within 7 days. Urine output < 0.5 mL/kg/hr for 6–12 hrs.
Setting: Ward — monitor, review nephrotoxins
Stage 2
KDIGO Stage 2
Creatinine 2.0–2.9× baseline. Urine output < 0.5 mL/kg/hr for ≥ 12 hrs.
Setting: Senior review, nephrology consultation
Stage 3
KDIGO Stage 3
Creatinine ≥ 3× baseline OR ≥ 353.6 µmol/L, OR initiation of RRT. Urine output < 0.3 mL/kg/hr for ≥ 24 hrs or anuria ≥ 12 hrs.
Setting: ICU / HDU — consider RRT initiation
Urine Microscopy & Diagnosis
Urinalysis with phase-contrast microscopy is a cornerstone in differentiating ATN from other causes of AKI. It is inexpensive, immediately available, and provides high diagnostic yield.
Microscopic Findings in ATN
Essential
Muddy-brown granular casts
Pathognomonic of ATN. Composed of degenerated tubular epithelial cell remnants and Tamm-Horsfall protein. Found in the distal nephron and collecting ducts.
Essential
Renal tubular epithelial (RTE) cells
Sloughed RTE cells may be present individually or as clusters. Intact RTE cells have a large nucleus with prominent nucleoli, distinguishing them from white blood cells.
Supportive
RTE cell casts
Casts containing sloughed RTE cells confirm ATN when present alongside granular casts.
Supportive
Coarse granular casts
Result from further degradation of fine granular casts; also indicative of tubular injury.
Not expected
RBC casts
Absence of red cell casts helps distinguish ATN from glomerulonephritis or vasculitis. If RBC casts are present, consider RPGN, lupus nephritis, IgA nephropathy.
Differential Diagnosis Based on Urine Sediment
| Diagnosis | Urine Sediment Findings | Other Distinguishing Features |
|---|---|---|
| ATN | Muddy-brown granular casts, RTE cells, RTE cell casts | FENa > 2 %, isosthenuria |
| Pre-renal AKI | Bland (hyaline casts only, no cells/casts) | FENa < 1 %, responds to volume |
| Acute interstitial nephritis | WBC casts, eosinophiluria (Hansel stain > 1 %), sterile pyuria | Fever, rash, eosinophilia; drug history (PPIs, NSAIDs, antibiotics) |
| Glomerulonephritis | RBC casts, dysmorphic RBCs, proteinuria | Active urinary sediment; consider serological workup (ANCA, anti-GBM, C3/C4) |
| Tubular obstruction | Urate crystals, oxalate crystals, myoglobinuria | Tumour lysis, ethylene glycol ingestion, rhabdomyolysis |
Biomarkers (Emerging & Available in Australia)
Several novel biomarkers may assist in early detection and differentiation of ATN:
- NGAL (Neutrophil gelatinase-associated lipocalin): Rises within 2–4 hours of tubular injury. Available at select tertiary laboratories (MBS item pending broader availability). Sensitivity ~90 % for ATN, but not specific — also elevated in interstitial nephritis and CKD.
- KIM-1 (Kidney injury molecule-1): Proximal tubular injury marker; urinary KIM-1 is highly specific for ischaemic nephrotoxic ATN. Primarily a research tool at present.
- TIMP-2 × IGFBP-7 (NephroCheck®): Cell-cycle arrest markers predicting AKI 12–24 hours before creatinine rise. Used in some Australian ICUs.
- Urinary [TIMP-2]·[IGFBP-7]: FDA/TGA-approved; values > 0.3 indicate high risk; > 2.0 very high risk.
Renal biopsy: Biopsy is not routinely required for the diagnosis of typical ATN. It should be considered when the aetiology is uncertain, when ATN fails to improve within 3–4 weeks, or when alternative diagnoses (e.g., AIN, glomerulonephritis, cortical necrosis) are suspected. Typical ATN findings on biopsy include flattening and loss of brush border of proximal tubular cells, apoptosis, necrosis, and luminal cast material.
Management & Prevention
Supportive Management of Established ATN
There is no specific pharmacological agent proven to reverse established ATN. Management is directed at maintaining homeostasis, preventing complications, and allowing tubular recovery.
1
Haemodynamic optimisation
Target MAP ≥ 65 mmHg (≥ 75 mmHg in septic shock with pre-existing hypertension). Use isotonic crystalloid (0.9 % NaCl or balanced solutions such as Hartmann's) for fluid resuscitation. Avoid excessive fluid administration — aim for euvolaemia. Inotropes/vasopressors as required. Avoid nephrotoxic vasopressors when possible (e.g., high-dose noradrenaline is acceptable; consider vasopressin adjunct).
2
Nephrotoxin cessation and avoidance
Immediately cease or substitute offending nephrotoxins: stop aminoglycosides, convert IV amphotericin B to liposomal formulation (AmBisome®), use paracetamol or topical NSAIDs instead of oral/IV NSAIDs, hold metformin in AKI. Review all medications via MedChart/eMR for renal dose adjustments.
3
Electrolyte management
Treat hyperkalaemia (calcium gluconate 10 % 10–20 mL IV over 2–5 min for cardiac protection; insulin 10 units in 50 mL 50 % dextrose IV; salbutamol 10–20 mg nebulised; sodium bicarbonate 8.4 % 50–100 mL if pH < 7.2; sodium zirconium cyclosilicate or patiromer for non-emergent cases). Correct metabolic acidosis (target pH > 7.2; consider sodium bicarbonate infusion 8.4 % at 1–1.5 mL/kg/hr diluted in 5 % dextrose). Monitor phosphate, calcium, and magnesium.
4
Fluid and sodium balance
Restrict sodium to < 100 mmol/day in oliguric patients. Restrict fluid intake to replace insensible losses + urine output (typically 500–600 mL insensible + urine output). Daily weight. Monitor for pulmonary oedema. Loop diuretics (frusemide 40–250 mg IV) may be used for volume overload but do NOT improve renal outcomes.
5
Nutrition
Enteral nutrition preferred. Protein 0.8–1.0 g/kg/day (non-catabolic) to 1.2–1.5 g/kg/day (catabolic / on RRT). Avoid potassium-rich and phosphate-rich foods. Dietitian consultation for all patients with AKI stage ≥ 2.
Indications for Renal Replacement Therapy (RRT)
Emergency indications for RRT: Refractory hyperkalaemia (K⁺ > 6.5 mmol/L unresponsive to medical therapy), severe metabolic acidosis (pH < 7.1), refractory pulmonary oedema, uraemic pericarditis, uraemic encephalopathy (confusion, seizures, coma), and drug toxicity with dialysable agents (lithium, methotrexate, ethylene glycol).
RRT modalities in Australian settings:
- Intermittent haemodialysis (IHD): Standard for haemodynamically stable patients. Available at all Australian tertiary centres and many regional centres (e.g., via SA Health, QLD Health renal networks).
- Continuous renal replacement therapy (CRRT): CVVHDF preferred in haemodynamically unstable / ICU patients. Dose target: effluent rate 25–35 mL/kg/hr.
- Sustained low-efficiency dialysis (SLED): Hybrid modality (6–12 hrs); increasingly used in Australian ICUs as an alternative to CRRT.
- Peritoneal dialysis (PD): Rarely used for AKI in Australia except in select remote settings or paediatric patients.
Prevention of ATN
1
Pre-procedural hydration
Contrast-induced AKI (CI-AKI) prevention: 0.9 % NaCl 1 mL/kg/hr IV for 6–12 hours before and 6–12 hours after contrast administration in at-risk patients (eGFR < 45 mL/min, diabetic nephropathy, heart failure). Alternative: sodium bicarbonate 154 mmol/L in 5 % dextrose 3 mL/kg/hr for 1 hour pre-contrast, then 1 mL/kg/hr for 6 hours post.
2
Perioperative optimisation
Maintain euvolaemia peri-operatively. Avoid hypotension during anaesthesia (MAP < 60 mmHg associated with ATN). Goal-directed fluid therapy in major surgery. Avoid nephrotoxin combinations.
3
Sepsis resuscitation
Early, aggressive fluid resuscitation (30 mL/kg crystalloid within 3 hours of sepsis recognition). Reassess volume responsiveness. Avoid unnecessary vasopressor delays.
4
Aminoglycoside stewardship
Extended-interval (once-daily) dosing (e.g., gentamicin 5–7 mg/kg OD) is less nephrotoxic than thrice-daily dosing. Therapeutic drug monitoring (TDM) — check trough before 3rd dose; target trough < 1 mg/L. Limit duration to 3–5 days where possible. Concurrent vancomycin increases risk — monitor closely.
5
Tumour lysis prophylaxis
Rasburicase (Fasturtec®) 0.2 mg/kg IV for high-risk patients (prevents urate crystallisation). Adequate hydration. Allopurinol for prophylaxis in lower-risk patients.
Pharmacological Adjuncts & Experimental Therapies
No proven specific therapy: Multiple agents (dopamine "renal dose", fenoldopam, atrial natriuretic peptide, loop diuretics, mannitol) have been studied but none have demonstrated a mortality benefit or improvement in ATN outcomes. Their use is not recommended for treatment of established ATN outside clinical trials.
Isotonic Crystalloid (0.9 % Sodium Chloride)
Normal Saline · IV Fluid · Fluid Resuscitation
Adult dose
1–2 L bolus (resuscitation); then 1–2 mL/kg/hr maintenance
Paediatric dose
20 mL/kg bolus over 20 min; reassess; maximum 60 mL/kg
Route
IV
Renal adjustment
Avoid excessive fluid loading in oliguric AKI; strict I/O balance
PBS status
✔ PBS General Benefit
Frusemide (Furosemide)
Lasix® · Loop Diuretic
Adult dose
40–250 mg IV; infuse < 4 mg/min to avoid ototoxicity
Paediatric dose
0.5–1 mg/kg IV; max 5 mg/kg/day
Route
IV / Oral
Renal adjustment
Higher doses may be needed in AKI; does not alter ATN course
PBS status
✔ PBS General Benefit
Sodium Bicarbonate
NaHCO₃ 8.4 % · Alkalinising Agent
Adult dose
50–100 mL of 8.4 % (50–100 mmol) IV over 15–30 min for acute acidosis; infusion 8.4 % at 1–1.5 mL/kg/hr diluted in 5 % Dextrose for continuous correction
Route
IV (central line preferred for continuous infusion)
Renal adjustment
Monitor for volume overload and hypokalaemia; reduce dose as pH improves
PBS status
✔ PBS General Benefit
Rasburicase
Fasturtec® · Recombinant Urate Oxidase
Adult dose
0.2 mg/kg IV over 30 min (single dose); may repeat if uric acid > 420 µmol/L
Paediatric dose
0.2 mg/kg IV (single dose)
Contraindication
G6PD deficiency — risk of severe haemolysis and methaemoglobinaemia
PBS status
✔ PBS Authority Required
Special Populations
Paediatrics
KDIGO criteria — applied using age-adjusted creatinine reference ranges. Neonates have lower baseline creatinine.
Fluid resuscitation — 20 mL/kg 0.9 % NaCl bolus; reassess after each bolus. Maintenance with standard Holliday-Segar formula (adjusted for losses).
RRT — CRRT preferred in neonates/small infants; PD may be used in resource-limited settings. Paediatric nephrology referral early.
Medications — Aminoglycoside toxicity is proportionally higher in children. Extended-interval dosing and TDM mandatory.
Rhabdomyolysis-induced ATN is increasingly recognised in paediatric settings (prolonged surgery, accidental trauma, viral myositis).
Pregnancy
Pregnancy-specific causes — Pre-eclampsia/HELLP syndrome, haemolytic uraemic syndrome (HUS), acute fatty liver of pregnancy, post-partum haemorrhage with shock.
Diagnosis — FENa may be unreliable due to pregnancy-related GFR changes. Ultrasound to exclude bilateral ureteric obstruction (enlarged gravid uterus).
Management — Delivery of the fetus may be necessary in severe pre-eclampsia/eclampsia. RRT can be safely performed during pregnancy (IHD or CRRT).
Medications — Avoid ACEi/ARB (teratogenic). Loop diuretics and antihypertensives: labetalol, nifedipine, hydralazine are preferred.
Elderly
Reduced GFR reserve — Age-related nephron loss increases susceptibility. ATN may develop with lesser insults.
Polypharmacy — High prevalence of NSAIDs, ACEi/ARB, diuretics, and aminoglycosides. Regular eGFR-based medication reviews.
Creatinine masking — Low muscle mass may mask rising creatinine. Urine output monitoring is crucial.
Goals of care — Discuss ceiling of treatment early. RRT may not improve quality-adjusted survival in frail elderly; consider conservative management pathway.
Chronic Kidney Disease (CKD)
Acute-on-chronic AKI — Pre-existing CKD dramatically increases ATN risk. Baseline creatinine is critical for AKI staging.
FENa unreliable — Use FEUrea (> 35 %) instead. CKD patients with nephrotic syndrome may have low FENa even with ATN.
Medication adjustments — Metformin: withhold if eGFR < 30 or in any AKI. SGLT2 inhibitors: pause during AKI. DOACs: dose-adjust by eGFR; monitor for accumulation.
RRT threshold — Lower threshold for RRT initiation in CKD patients who are already near-dialysis (eGFR < 15).
Hepatic Impairment
Hepatorenal syndrome (HRS) — Distinguish from ATN: HRS has low FENa (< 1 %), bland sediment, low urine sodium, and responds (transiently) to volume + terlipressin (PBS Authority Required).
Acute tubular necrosis vs HRS — Urine microscopy with muddy-brown casts confirms ATN. Simultaneous ATN and HRS can occur.
RRT — CRRT preferred (heparin-free circuit if coagulopathic). MARS® (molecular adsorbent recirculating system) available at select liver transplant centres.
Immunocompromised
Nephrotoxin exposure — Immunosuppressed patients frequently receive aminoglycosides, amphotericin, vancomycin, calcineurin inhibitors (tacrolimus, cyclosporin) — each can cause ATN.
Calcineurin inhibitor nephrotoxicity — Trough monitoring (tacrolimus 5–10 ng/mL, cyclosporin 100–200 ng/mL). Drug levels must be checked with every creatinine rise.
BK virus nephropathy — Mimics ATN post-renal transplant. Urine decoy cells, BK viral load (PCR). Reduce immunosuppression.
Tumour lysis — Haematological malignancies treated with high-dose chemotherapy. Aggressive prophylaxis with rasburicase + hydration.
Aboriginal and Torres Strait Islander Health Considerations
Aboriginal and Torres Strait Islander Health
Aboriginal and Torres Strait Islander Australians experience significantly higher rates of acute kidney injury (AKI) compared with non-Indigenous Australians. According to the Australian Institute of Health and Welfare (AIHW), Indigenous Australians are 1.5–2 times more likely to be hospitalised with AKI and have significantly higher rates of AKI requiring renal replacement therapy, particularly in remote and very remote communities.
Recommended actions for clinicians: (1) Use a lower threshold for AKI screening in Indigenous patients presenting with dehydration, sepsis, or nephrotoxin exposure. (2) Engage AHWLOs early. (3) Ensure adequate hydration in remote communities — water security is a health issue. (4) Provide post-AKI CKD surveillance plans and communicate with primary healthcare teams. (5) Use remote prescribing guidelines (e.g., CARPA Standard Treatment Manual) for area-specific protocols.
📚 References
- 1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International. 2024;105(4S):S117–S314.
- 2. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney International Supplements. 2012;2(1):1–138.
- 3. Kellum JA, Lameire N, Aspelin P, et al. Kidney Disease: Improving Global Outcomes (KDIGO) Work Group on Contrast-induced AKI: KDIGO Clinical Practice Guideline for Acute Kidney Injury — Contrast-induced AKI section. Kidney International Supplements. 2012;2:69–88.
- 4. Australian Institute of Health and Welfare (AIHW). Chronic kidney disease: Australian facts. Cat. no. PHE 220. Canberra: AIHW; 2023.
- 5. Mårtensson J, Bellomo R. The rise and fall of NGAL in acute kidney injury. Blood Purification. 2014;37(4):304–310.
- 6. Kashani K, Al-Khafaji A, Ardiles T, et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Critical Care. 2013;17(1):R25.
- 7. Palevsky PM, Zhang JH, O'Connor TZ, et al. Intensity of renal support in critically ill patients with acute kidney injury. New England Journal of Medicine. 2008;359(1):7–20.
- 8. Bellomo R, Cass A, Cole L, et al. Intensity of continuous renal-replacement therapy in critically ill patients. New England Journal of Medicine. 2009;361(17):1627–1638 (RENAL Study).
- 9. National Health and Medical Research Council (NHMRC). Australian guidelines for the prevention and control of infection in healthcare. Canberra: NHMRC; 2019 (referenced for aminoglycoside stewardship principles).
- 10. Australasian Society for Infectious Disease (ASID). Australian Commission on Safety and Quality in Health Care — Antimicrobial Stewardship Clinical Care Standard. Sydney: ACSQHC; 2023.
- 11. Lameire N, Van Biesen W, Vanholder R. Acute kidney injury. Lancet. 2008;372(9653):1863–1865.
- 12. Ronco C, Bellomo R, Kellum JA. Acute kidney injury. Lancet. 2019;394(10212):1949–1964.
- 13. Liangos O, Wald R, O'Bell JW, Price L, Pereira BJG, Jaber BL. Epidemiology and outcomes of acute renal failure in hospitalized patients: a national survey. Clinical Journal of the American Society of Nephrology. 2006;1(1):43–51.
- 14. RACGP. Red Book — Guidelines for preventive activities in general practice. 10th edn. Melbourne: RACGP; 2024 (referenced for CKD screening recommendations).
- 15. McDonald S, Hurst K. ANZDATA Registry Report 2023. Adelaide: Australia and New Zealand Dialysis and Transplant Registry; 2023.